2.1
Daratumumab (Darzalex, Johnson & Johnson) is indicated 'in combination with bortezomib, lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma'.
2 Information about daratumumab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for daratumumab.
Price
2.3
The list price for daratumumab is £4,320 per 1,800 mg/15 ml vial (excluding VAT; BNF online accessed May 2026).
2.4
The company has a commercial arrangement. This makes daratumumab available to the NHS with a discount. The size of the discount is commercial in confidence.
Sustainability
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on Johnson & Johnson's webpage on their responsibility to the planet.